264 related articles for article (PubMed ID: 17216861)
1. Anti-HIV agents. Abacavir--as good as AZT?
TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
[No Abstract] [Full Text] [Related]
2. Triple nuke therapy--results after one year.
TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
[No Abstract] [Full Text] [Related]
3. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Gallant JE
Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
[No Abstract] [Full Text] [Related]
4. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
Tasias M; Ruiz S; Deig E; Pedrol E
Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
[No Abstract] [Full Text] [Related]
5. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
[No Abstract] [Full Text] [Related]
6. Anti-HIV agents. Abacavir once or twice daily.
TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
[No Abstract] [Full Text] [Related]
7. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
8. Abacavir: new preparation. Risks limit the value.
Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
[No Abstract] [Full Text] [Related]
10. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Feinberg J
AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
[No Abstract] [Full Text] [Related]
11. [First HIV triple therapy with one tablet].
Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
[No Abstract] [Full Text] [Related]
12. Abacavir arm stopped in clinical trial.
James JS
AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
[TBL] [Abstract][Full Text] [Related]
13. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Moyle GJ
AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
[No Abstract] [Full Text] [Related]
14. New drugs: amprenavir and abacavir.
TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
[TBL] [Abstract][Full Text] [Related]
15. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Moyle GJ; Gazzard BG
AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
[No Abstract] [Full Text] [Related]
16. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Feinberg J
AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
[No Abstract] [Full Text] [Related]
17. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
18. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
Srikantiah P; Walusimbi MN; Kayanja HK; Mayanja-Kizza H; Mugerwa RD; Lin R; Charlebois ED; Boom WH; Whalen CC; Havlir DV
AIDS; 2007 Sep; 21(14):1972-4. PubMed ID: 17721107
[TBL] [Abstract][Full Text] [Related]
19. New formulations approved for children.
AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
[No Abstract] [Full Text] [Related]
20. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
